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Zealand; 4South Auckland Clinical School, University of Auckland, Middlemore, Auckland, New ZealandA B S T R A C TObjective: To establish the cost-effectiveness of long-term humidiﬁ-
cation therapy (LTHT) added to usual care for patients with moderate
or severe chronic obstructive pulmonary disease or bronchiectasis.
Methods: Resource usage in a 12-month clinical trial of LTHT was
estimated from hospital records, patient diaries, and the equipment
supplier. Health state utility values were derived from the St. Georges
Respiratory Questionnaire (SGRQ) total score. All patients who
remained in the trial for 12 months and who had at least 90 days of
diary records were included (87 of 108). Results: Clinical costs were
NZ $3973 (95% conﬁdence interval [CI] $1614–$6332) for the control
group and NZ $3331 (95% CI $948–$6920) for the intervention group.
The mean health beneﬁt per patient was 6.9 SGRQ units (95% CI
13.0 to 7.2; P o 0.05) or þ0.0678 quality-adjusted life-years (95% CI
0.001–0.135). With the intervention costing NZ $2059 annually, the
mean cost per quality-adjusted life-year was NZ $20,902 (US $18,907)
and the bootstrap median was NZ $19,749 (2.5th percentile $40,923,
97.5th percentile $221,275). At a willingness-to-pay (WTP) threshold ofee front matter Copyright & 2014, International S
r Inc. This is an open access article under the CC
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land.NZ $30,000, the probability of cost-effectiveness was 61%, ranging
from 49% to 72% as the cost of LTHT was varied by 30%. At a WTP of
NZ $20,000, the probability was 49% (range 34%–61%). Conclusions:
LTHT is moderately cost-effective for patients with moderate to
severe chronic obstructive pulmonary disease or bronchiectasis at a
WTP threshold that is acceptable for public funding of medicines in
New Zealand. These ﬁndings must be interpreted with caution
because of the modest size of the clinical study, necessary lack of
blinding in the clinical trial, and uncertainty in estimating health state
utility from the SQRQ.
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Chronic obstructive pulmonary disease (COPD) is deﬁned by the
Global Initiative on Chronic Obstructive Lung Disease [1] as “… a
common preventable and treatable disease characterised by per-
sistent airﬂow limitation that is usually progressive and associated
with an enhanced chronic inﬂammatory response in the airways
and the lung to noxious particles or gases.” According to the latest
World Health Organization update (2008), currently 64 million
people have COPD and 3 million people died of COPD in 2004.
TheWorld Health Organization predicts that COPD will become the
third leading cause of death worldwide by 2030 [2]. The cost to the
UK National Health Service was estimated at £486 million to £848
million per year over a decade ago, and the cost to society could
bring this to almost £1000 million [3]. The major drivers of this cost
burden are the severity of disease and exacerbations. Productivity
losses can be substantial because of time off work due to illness.
According to British Thoracic Society guidelines [4], bronchiec-
tasis is a persistent or progressive condition characterised bydilated thick-walled bronchi. The symptoms vary from intermittent
episodes of expectoration and infection localised to the region of
the lung that is affected to persistent daily expectoration often of
large volumes of purulent sputum.
Persistent airway inﬂammation with mucus retention in
patients with chronic airway disorders such as COPD and bron-
chiectasis can lead to frequent exacerbations, reduced lung
function, and poor quality of life. A range of therapies is available,
including smoking cessation, pneumococcal and inﬂuenza vac-
cination, physiotherapy, pulmonary rehabilitation, short-acting
and long-acting inhaled bronchodilators, corticosteroids, and
antibiotics. Long-term oxygen therapy is used for some patients
with very severe COPD, and lung volume reduction surgery and
transplantation are also available for selected patients [1,5].
Many patients with bronchiectasis have airﬂow obstruction,
so the therapies used are similar to those used for COPD,
including inhaled short- and long-acting bronchodilators and
inhaled corticosteroids. Bacterial infection is more pronounced
in bronchiectasis, so antibiotics may be used more frequently.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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iotherapy are also commonly used.
New Zealand has prevalence rates for COPD that are similar to
those of other developed countries [6]. The prevalence of bron-
chiectasis has not been reported but exacerbations of bronchiec-
tasis in South Auckland are more common in patients who are
predominantly of Māori or Paciﬁc descent and are socioeconomi-
cally deprived [7]. Australasian and US Guidelines are followed
for clinical management [8,9].
The St. George’s Respiratory Questionnaire (SGRQ) is a self-
administered questionnaire containing 40 items with weighted
responses divided into three components: symptoms, activity, and
impacts. The “symptoms” component contains items concerned
with the level of trouble due to cough, sputum, wheeze, and
breathlessness. The “activity” component is concerned with phys-
ical activities. The “impacts” component covers employment, feel-
ings of control, panic, stigmatization, need for medication, and
disturbance of daily life. Scores ranging from 0 to 100 are calculated
for each component as well as a total score. A 0 score indicates no
impairment of quality of life. The questionnaire takes about 10
minutes to complete and has been shown to be reproducible, valid,
and responsive [10]. Although the SGRQ was designed initially for
COPD [10], it has also been validated for bronchiectasis [11].
A recent randomized controlled trial in New Zealand studied
long-term therapy with high-ﬂow fully humidiﬁed air, supple-
mented with oxygen if required, at 371C delivered through nasal
cannulae (long-term humidiﬁcation therapy [LTHT]) for patients
with moderate or severe COPD or bronchiectasis. The hypothesis
was that this might improve mucociliary clearance [12,13]. The
delivery device is very easy to use and requires no assistance.
When the LTHT is used to supplement usual care (the control
group), 12 months of therapy at a mean duration of 1.6 hours per
day improved lung function, reduced the number of days with an
exacerbation, increased the time to ﬁrst exacerbation, and
improved quality of life assessed by the SGRQ [10]. This therapy
entails capital expenditure and annual running costs, but its cost-
effectiveness has not been established.
The most generally accepted humanistic outcome of medical
interventions is the quality-adjusted life-year (QALY), which
combines quality of life with survival. The QALY is the preferred
outcome for assessment of health beneﬁts of novel pharmaceut-
icals for reimbursement in New Zealand [14]. The New Zealand
pharmaceutical reimbursement agency (PHARMAC) has nine
decision criteria for reimbursement, one of which is the incre-
mental cost-utility ratio (ICUR) or the incremental cost per QALY
gained by the intervention [14,15]. In the near future, this
measure could be adopted for formal assessment of selected
therapeutic medical devices. PHARMAC has been willing to pay
more than NZ $100,000 (about US $86,77) per QALY for some
innovative medicines. The weighted average ICUR across a range
of funded new therapies over the period 1998 to 2006, however,
was about NZ $20,000 per QALY [16]. This suggests that in
practice therapies with an ICUR of around this value would be
considered as providing good value for money, all other factors
being equal.
The purpose of this work was to provide an economic evaluation
of a previous clinical trial of administration of warmed humidiﬁed
air (oxygen enriched where clinically indicated) to patients with
moderate or severe COPD or bronchiectasis, delivered by an LTHT
device [4]. The perspective is that of the health care payer, namely,
the District Health Board and the patient jointly.Methods
In the source clinical study [12], 108 patients diagnosed with
COPD or bronchiectasis were randomized to LTHT plus usual careor usual care alone for 12 months. Disease exacerbations, lung
function, quality of life on the SGRQ [10], exercise capacity, and
measures of airway inﬂammation were recorded at baseline,
3 months, and 12 months where possible [12]. For the purposes
of the economic analysis, patients who did not discontinue from
the 12-month study were used (96 subjects) if they had at least
90 days of diary records of symptoms, medications, and medical
consultations (87 subjects). In a sensitivity analysis, we tightened
the criterion for days of diary records, which made more detailed
cost information available but reduced the number of subjects in
the analysis.
Costs (NZ $)
Fixed and variable costs of AIRVO® equipment ($4600), setup
($400), and consumables (heated breathing tubes and air ﬁlters)
were obtained from the manufacturer (Fisher & Paykel Health-
care Ltd; Auckland, New Zealand), and the cost was annualized
assuming an annual interest rate and discount rate of 3.5%, and
a 5-year lifetime for the equipment, estimated by the manufac-
turer [15]. Long-term oxygen therapy was excluded from cost
calculations because it will be used for selected patients with
very severe COPD, whether or not the LTHT equipment is used,
and its usage was not monitored systematically during the
clinical study. When the equipment is used in the community,
oxygen is supplied by an oxygen concentrator at a monthly
rental cost that is independent of the daily hours of use. Water
and electricity costs are trivial and were excluded from the
analysis.
Details of hospital admissions were obtained from adminis-
trative records of patients in the clinical trial, and all other
medical costs were estimated from the patient daily diaries.
These included costs for visits to the emergency department,
emergency doctor, or general practitioner (GP) and use of anti-
biotics and prednisone. Insufﬁcient detail was available for
analysis of the usage of other medications. Diary data were pro
rata standardized to 365 days.
The cost of hospital admissions that were judged by the
clinical investigators as “respiratory” (e.g., exacerbations of COPD
or pneumonia) were estimated as follows: The principal International Statistical Classiﬁcation of Diseases,
10th Revision diagnosis of each respiratory admission was
determined from hospital records. For each of these diagnoses, a cost weight was determined as
the mean of 15,482 respiratory admissions in New Zealand
recorded in the National Minimum Data Set over the period
January 1, 2011, to December 31, 2011 (source: NZ Health
Information Service). The cost weight was multiplied by the national cost for 2012-
2013 ($4614) obtained from the Ministry of Health.
Details of medication usage were available only for predni-
sone and antibiotics, although other medications including tio-
tropium were used by some patients. Costs of prednisone and
antibiotics were obtained from the national pharmaceutical
schedule [17], and the cost of emergency care and GP consulta-
tions was obtained from estimates by PHARMAC [18] because
better sources of information that apply to the whole country are
not available. The cost of an emergency doctor was estimated
from Auckland after-hours clinics at two locations. Co-payments
on pharmaceuticals were costed at $5.00 per item [17] and a
dispensing fee of $5.30 per item was added to the cost [18].
Other relevant information such as district nursing service
and home help was not available from patient diaries and
therefore was not included in the analysis. These costs are
unlikely to be modiﬁed by the intervention, at least in the short
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intervention minus the potential cost savings attributable to the
intervention (if any).
Economic Outcomes and Analyses
The total score on the SGRQ, which is a measure of quality of life,
differed signiﬁcantly (P ¼ 0.029) between the two arms of the
clinical trial [12]. It was considered appropriate to use this as the
outcome in the economic analysis because a mapping between
SGRQ and health state utility is now available (see below). SGRQ
total scores were obtained from questionnaires completed at
baseline, 3 months, and 12 months, and exacerbation days were
obtained from patient diaries. Because SGRQ total scores were
similar at 3 months and 12 months [12], only baseline and 12-
month scores were used in the analysis.
The total SGRQ score for each patient at baseline and at 12
months was mapped to a health state utility based on the
EuroQol ﬁve-dimensional (EQ-5D) questionnaire assessment
instrument using the following algorithm derived from the
Towards a Revolution in COPD Health (TORCH) study of salme-
terol/ﬂuticasone in patients with moderate to very severe COPD [19]:
Utility¼ 0.9617  0.0013  SGRQ  0.0001  SGRQ2 þ 0.0231 M
where SGRQ is the total SGRQ score andM is 1 for male or 0 for
female. The utility gain or loss over 12 months for each patient
was taken as the difference between the 12-month utility and the
baseline utility. Missing incremental utilities (two in the treat-
ment group and one in the control group) were imputed by
replacement with the mean of all other incremental utilities in
the corresponding treatment group, based on all 96 subjects who
remained in the clinical trial for at least 12 months. The mean
utility gain or loss in each arm of the study was then calculated
[20], and the mean ICUR was calculated as the difference in costs
between the treatment and control arms divided by the differ-
ence in mean health state utilities. Because the distribution of the
ICUR is unknown, we expressed the uncertainty in the ICUR using
a nonparametric bootstrap method [21]. The time horizon of the
economic analysis was 12 months.
The results of the bootstrap analysis were plotted on a scatter
graph and on a cost-effectiveness acceptability graph to illustrate
the degree of uncertainty [21–23]. Then, the probability of the
intervention being cost-effective for a given willingness-to-payTable 1 – Respiratory admissions for 87 patients in the 1
Principal diagnosis (IC)D10 No. Cost per
admission ($)*
Cos
J440 22 4,767 104
J441 9 4,767 42
J47 7 4,471 31
J459 3 2,676 8
J22 2 3,022 6
J189 2 5,482 10
J14 1 5,482 5
J069 1 3,022 3
R060 1 2,118 2
J201 1 3,022 3
R042 1 2,118 2
Total 50 219
DRG, diagnosis-related group; LTHT, long-term humidiﬁcation therapy.
*Based on 15,482 admissions in 2011 for patients 20 y of age or older; us
$4614).(WTP) threshold λ was deﬁned as the proportion of iterations
lying below the diagonal line representing parameter λ on the
scatter graph. The value of λ was then varied from $20,000 to
$50,000 per QALY, representing the potential preferences of New
Zealand health care decision makers for accepting the
intervention.
Analyses were carried out using Stata version 12.1 and SAS
version 9.3.1 and a template spreadsheet for bootstrap analysis
developed by the UKMedical Research Council Biostatistics Unit [24].
Tests were two-sided, and the level of signiﬁcance was set at 0.05.Results
Medical Costs
Total medical costs per patient over the 12 months of the clinical
trial include those for hospital admissions, emergency depart-
ment presentations, emergency doctor and GP consultations,
antibiotics, and prednisone. Information on other medications
was not collected systematically in the clinical trial and therefore
could not be analyzed.
For the 87 patients included in the analysis, there were 11
different International Statistical Classiﬁcation of Diseases, 10th Revi-
sion principal diagnoses for 50 respiratory admissions (27 in the
treatment group and 23 in the control group). Pneumonia
accounted for 6% of principal diagnoses. The diagnosis-related
group (DRG)-based admission cost at 2012-2013 prices varied
from $2118 to $5482 (Table 1).
Usage of prednisone and antibiotics was common, and GP
consultations averaged about one every 8 weeks. Treated patients
consumed signiﬁcantly fewer antibiotics, as reported previously
[12], but usage of other resources did not differ signiﬁcantly
between treatment and control groups. Excluding hospital admis-
sions, in the treated group the costs were highest for GP
consultations, with some patients consulting weekly, and lowest
for pharmaceuticals, whereas in the control group, emergency
care predominated (Table 2).
Hospital admission costs were added to community costs.
Over 12 months of the clinical trial, the total cost per patient
(excluding the intervention) was 16% lower in the treated group
(Table 2) but the difference between treatment and control
groups was not statistically signiﬁcant. Admission costs2-month clinical trial of LTHT.
t ($) Description
,866 Chronic obstructive pulmonary disease with acute lower
respiratory tract infection
,900 Chronic obstructive pulmonary disease with acute
exacerbation, unspeciﬁed
,299 Bronchiectasis
,029 Asthma, unspeciﬁed
,045 Unspeciﬁed acute lower respiratory tract infection
,964 Pneumonia, unspeciﬁed
,482 Pneumonia due to Haemophilus inﬂuenzae
,022 Acute upper respiratory tract infection, unspeciﬁed
,118 Dyspnea
,022 Acute bronchitis due to H. inﬂuenzae
,118 Hemoptysis
,865
ing national DRG cost weights and 2012/13 costs (national DRG price
Table 2 – Resource usage and annualized costs excluding the intervention for 87 patients participating in the
12-mo clinical trial of LTHT.
Item Treatment (n ¼ 48) Control (n ¼ 39)
Mean 95% CI þ95% CI Mean 95% CI þ95% CI
Resources per patient
Antibiotics (d) 75.7 50.7 100.7 118.3 80.9 155.7
Prednisone (d) 60.2 33.1 87.3 55.4 24.8 86.0
GP consultation 7.2 4.4 10.1 8.6 5.1 12.2
Emergency doctor consultations 0.49 0.04 1.03 1.96 0.20 3.71
Emergency care 0.72 0.19 1.25 1.53 0.14 3.20
Admissions 0.56 0.23 0.89 0.59 0.16 1.02
Hospital days 1.33 0.28 2.39 1.82 0.35 3.29
Average length of stay 2.06 1.54 2.58 2.91 1.44 4.37
Costs per patient ($)
Antibiotics 17.42 11.67 23.18 27.22 18.61 35.83
Prednisone 4.94 2.71 7.16 4.54 2.04 7.05
GP consultations 471 286 838 560 330 791
Emergency doctor 39 3 194 156 16 297
Emergency care 325 88 1,075 689 63 1,440
Admissions 2,474 948 6,920 2,536 626 4,445
Total 3,331 1,696 7,411 3,973 1,614 6,332
COPD 3,562 1,874 5,250 4,280 1,663 6,897
Bronchiectasis 3,699 1,336 6,062 2,002 729 3,275
Incremental cost 642
Note. Days are annualized days.
CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; GP, general practitioner; LTHT, long-term humidiﬁcation therapy.
*P o 0.05.
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group and three-quarters in the treated group.
Cost of Equipment
The LTHT AIRVO® equipment has an estimated lifespan of 5
years and is expected to cost NZ $4600 retail plus an initial setup
cost of $400. The annualized cost of equipment plus consumables
was $2059. This cost could potentially be borne by the health care
purchaser or the patient.
Quality of Life
The number of exacerbation-free days during the study repre-
sents a crude but widely used measure of quality of life. In the
source clinical trial of 108 patients, there were 18.2 exacerbation
days in the treatment group and 33.5 in the control group (P ¼
0.045). In our analysis of 87 patients from this clinical trial, there
were also fewer days with an exacerbation in the treatment
group than in the control group (21.3 vs. 34.1) but the difference
did not reach statistical signiﬁcance, probably because the num-
ber of subjects in the study group was insufﬁcient for this end
point. An economic analysis using exacerbation-free days was
not conducted because it is a surrogate outcome and an indirect
link to QALYs was available through the SGRQ.
The total score on the SGRQ is a disease-speciﬁc measure of the
health-related quality of life of patients with respiratory diseases
including COPD or bronchiectasis [10]. As in the source study,
baseline total SGRQ scores did not differ signiﬁcantly between
patients with principal diagnoses of bronchiectasis or COPD. Incre-
mental SGRQ and derived incremental utility scores were normally
distributed. Combining COPD and bronchiectasis and comparing
the active treatment group at 12 months with the control group
gave a decline of 6.9 points (95% conﬁdence interval [CI] 7.2–13.0) in
mean SGRQ score and an increase of 0.068 (95% CI 0.001–0.135) in
patient-by-patient mapped incremental utility (Table 3).Economic Outcomes
The cost-effectiveness of the intervention is deﬁned as the
incremental cost divided by the incremental health beneﬁt
expressed as QALYs. The mean cost-utility ratio in the base-
case analysis was $20,907 per QALY (Table 4).
To estimate the uncertainty in the ICUR, a bootstrap simu-
lation using 5000 replicates was performed (see Methods). When
pairs of incremental costs and incremental health beneﬁts were
plotted, most values (81%) generated by the bootstrap simulation
lay in the top right quadrant of the cost-effectiveness plane,
indicating greater cost and greater health gain (Fig. 1). Some of
the remaining points (17% of the total) indicate a positive health
beneﬁt at lower cost (“dominance”).
The median ICUR obtained by bootstrapping (NZ $19,749; 2.5th
percentile $40,923, 97.5th percentile $221,275) was similar to the
mean that was determined from the ratio of the mean costs and
mean utilities ($20,907).
The cost-effectiveness acceptability curve (Fig. 2) shows that
at a WTP threshold of NZ $20,000, the probability of being cost-
effective was 49%, ranging from 34% to 61% as the cost of the
intervention (LTHT equipment plus running costs) was varied by
30%. At a WTP threshold of NZ $30,000, the probability of LTHT
being cost-effective was 61% (range 49%–72%).
Finally, our criterion for the selection of subjects for the econo-
mic evaluation was based on the number of completed diary days.
For the base-case analysis, we used at least 3 months’ worth of
diary data. This has the advantage of including most (92%) of the
nondiscontinued patients. However, it has the disadvantage that
up to 9 months of community cost data and exacerbations must
be extrapolated from 3 months of diary records for some patients.
With a more stringent cutoff of 9 months of diary records, no more
than 3 months of diary data are missing, but fewer subjects (70,
not 87) are selected for the analysis and the incremental health
beneﬁt and costs are both larger and the cost-utility ratio is
smaller (Table 5). In this respect, our analysis is conservative.
Table 3 – SGRQ and utility scores for COPD and
bronchiectasis.
Item No. of
patients
Mean 95%
CI
þ95%
CI
Exacerbation
days
Treatment group 48 21.3 9.8 39.6
Control group 39 34.1 11.8 68.7
SGRQ
Baseline
COPD 51 48.6 44.5 52.7
Bronchiectasis 36 47.9 42.5 53.3
Treatment
group
48 48.7 44.7 52.7
Control group 39 47.7 42.4 53.1
Combined
groups
87 48.3 45.0 51.5
Change in SGRQ
during 12-mo
study
Treatment 48 6.2 10.2 2.2
Control 39 0.7 4.0 5.4
Increment 6.9 13.0 7.2
Health state
utility
Baseline
Treatment
group
47 0.65 0.61 0.70
Control group 38 0.66 0.60 0.72
Combined 85 0.66 0.62 0.69
Change in utility
during 12-mo
study
Treatment 48 0.058 0.015 0.101
Control 39 0.009 0.060 0.041
Increment* 0.068 0.001 0.135
CI, conﬁdence interval; COPD, chronic obstructive pulmonary
disease; SGRQ, St George’s Respiratory Questionnaire.
*P o 0.05.
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This study is based on a 12-month randomized controlled trial of 108
patients with moderate or severe COPD or bronchiectasis conducted
in New Zealand. Because of withdrawals andmissing diary data, only
87 of these patients (80%) were included in the base-case analysis.Table 4 – Incremental costs, outcomes, and cost-
effectiveness.
Annualized capital expenditure $984
Annualized consumables $1,075
Total $2,059
Incremental clinical costs (12 mo) $643
Incremental costs $1,417
Incremental utility 0.068
ICUR (mean) $20,902
ICUR (median) $19,749
2.5th percentile $40,923
97.5th percentile $221,275
ICUR, incremental cost-utility ratio.
*The median and range were derived by bootstrapping.Cost of Illness
On the basis of a control group of 39 patients with at least 3
months of diary data, we estimate the annual cost of health care
delivery to individuals with moderate to severe COPD or bron-
chiectasis at $3973 (95% CI $1614–$9875). This includes all the
major costs to government plus patient co-payments for com-
munity doctors, antibiotics, and prednisone, but it excludes
district nursing care and home help, which were not tracked in
the clinical trial, and several community pharmaceuticals. Most
(64%) of the measured cost was due to respiratory admissions
including exacerbations of COPD and pneumonia. The total cost
is undoubtedly an underestimate because comorbidities such as
cardiovascular events that could be associated with COPD [25]
were not costed. Supplemental oxygen, although costly, was also
excluded (see Methods). A study in Israel of 389 adults with COPD
showed that health care utilization was 3 to 4 times higher for
patients with COPD than for the general population, due largely
to comorbidities [26], and a US claims-based analysis showed that
direct medical costs are driven largely by hospital admissions
[27], as our study also shows.
The source clinical trial reported that LTHT reduced the
number of days with an exacerbation, reduced the annual
number of days that patients required antibiotics, increased the
time to ﬁrst exacerbation, and improved quality of life assessed
on the SGRQ [12]. We found a trend toward reduction in resource
consumption and corresponding potential cost savings, but these
were not statistically signiﬁcant. A larger study that collects
resource consumption including oxygen usage in more detail is
required to establish the full effect of the LTHT device on costs.
Cost savings can be expected if the frequency of exacerbations is
reduced by an intervention [28,29].
Quality of Life
The SGRQ total score for 87 patients at baseline (48.3, 95% CI 45.0–
51.5) was similar to that found in international studies of patients
with moderate to severe COPD [30–32] and clinically stable
bronchiectasis [33] and within the range of UK values found in
the pivotal international 4-year clinical trial of tiotropium in
patients with COPD (UPLIFT [34]). Mean incremental SGRQ scores
in the source clinical trial improved (declined) between the
baseline and 3-month measurements and this beneﬁt was
maintained at 12 months. In our analysis, the SGRQ score fell
by 6.9 units (95% CI 7.2–13.0) corresponding to a gain of 0.068 (95%
CI 0.001–0.135) utility points. In a 12-month period, assuming that
the effect is achieved immediately, this amounts to a quality-of-
life gain of 0.068 QALYs. In comparison, the SGRQ total score for
patients receiving tiotropium was 3.3 units lower after 12 months
than for patients with COPD receiving ipratropium [31], 4 units
lower with tiotropium compared with placebo in UPLIFT [35], and
2.8 units lower after pulmonary rehabilitation [36,37]. A differ-
ence of 4 units in the SGRQ total score is considered by some
authors to be consistent with a clinically relevant change [38].
Health state utility values differ across studies and vary with
the type and severity of the disease [3]. In a subset of 1235 patients
included in UPLIFT, increased severity of COPD was associated
with signiﬁcantly lower EQ-5D questionnaire utility scores for
patients with COPD, with UK mean utility scores ranging from
0.787 (95% CI 0.771–0.802) for moderate COPD to 0.647 (95% CI
0.598–0.695) for very severe COPD [38,39]. Utility values in a US
study showed a similar pattern but were systematically higher at
each level of severity. The baseline mean utility in our study (0.65,
95% CI 0.60–0.70) is at the “very severe” end of this scale, even
though SGRQ scores were similar to those in the UK study. This
ﬁnding suggests that either social preferences for the EQ-5D
questionnaire differ between the United Kingdom and New Zea-
land [40] or the algorithm for converting from SGRQ to EQ-5D
Fig. 1 – Scatter plot of the ICUR on the cost-effectiveness plane (5000 bootstrap replicates). Sloping lines show possible values
of willingness to pay (λ). ICUR, incremental cost-utility ratio.
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The comparison between New Zealand and the United Kingdom is
somewhat blunted because of inclusion of patients with bron-
chiectasis in our study but not the UK study; however, the baseline
SGRQ score was similar for patients with both diagnoses.
The sensitivity of the EQ-5D questionnaire has been debated
because it does not include a respiratory domain [41]. Never-
theless, we were able to estimate changes in health state utility
using an indirect method based on a respiratory questionnaire.
The gain in health state utility in our analysis (0.068 points) is
greater than was achieved by tiotropium in UPLIFT (0.05 [39]) but
smaller than that in the TORCH trial (0.077 to 0.111) over a longer
period of time [42]. The reasons are that the total SGRQ score in
the control group remained stable over the 12-month period of the
trial and declined in the treatment group within the initial 3
months of the trial and was maintained at 12 months. Because the
study designs and patient groups differed between the therapies, it
is not possible to conclude which intervention is superior; in anyFig. 2 – Probability that long-term air humidiﬁcation will be
cost-effective at various willingness-to-pay thresholds.
Annualized LTHT cost ¼ $2059 including equipment and
consumables (base case). LTHT, long-term humidiﬁcation
therapy; WTP, willingness to pay.case, they are probably complementary. An important empirical
study suggested that the minimally important difference for the
EQ-5D questionnaire utility is 0.074 [43]. By this criterion, however,
few effective therapies for COPD would qualify.
Cost-Effectiveness
Various medications for COPD have received a full economic
evaluation [44,45]. A recent economic analysis of a 4-year major
clinical trial (UPLIFT) showed that tiotropium improved quality of
life by 0.05 discounted cumulative QALYs per patient compared
with usual care and achieved an ICUR of less than £16,000 per
QALY in the United Kingdom [39].
Because the LTHT intervention did not appear to generate cost
savings, the ICUR depends largely on the cost of the LTHT
intervention and the gain in quality of life. New Zealand reim-
burses new pharmaceuticals on the basis of nine explicit decision
criteria [46] and does not have a ﬁxed WTP threshold forTable 5 – The effect of selecting different numbers of
subjects for the analysis, based on completed diary
records.
Item Diary days
4269 4179 489*
Subjects, n (%)† 70 (73) 79 (82) 87 (91)
Baseline SGRQ score 46.8 48.5 48.3
Incremental cost ($)‡ 1,149 679 642
Incremental utility 0.0834 0.0755 0.0678
Mean ICUR ($)§ 10,910 18,272 20,907
ICUR, incremental cost-utility ratio; LTHT, long-term humidiﬁca-
tion therapy; SGRQ, St George’s Respiratory Questionnaire.
*Base case.
†Percentage of the 96 patients who remained in the clinical trial for
at least 12 mo.
‡Excludes the intervention.
§Mean ICUR ¼ (incremental cost þ LTHT cost)/(incremental utility).
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 2 0 – 3 2 7326reimbursement [47]. Although New Zealand does not yet have a
formal decision process for public funding of medical devices,
most of these decision criteria are relevant. The weighted mean
ICUR for new medicines that were reimbursed in New Zealand in
the period 1998-1999 to 2006-2007 was about NZ $20,000 per QALY
[16], implying that an ICUR of NZ $20,000 is well within the
acceptable range for new medicines, provided that other decision
criteria are met. Assuming that these criteria can be applied to
medical devices, this ﬁgure gives a conservative guide to an
acceptable ICUR. On this basis, at its most likely retail cost in New
Zealand, the LTHT intervention has a 49% probability of being
cost-effective. At a WTP threshold of NZ $30,000, which is more in
line with other countries, the probability increases to 61%.
Given a purchasing power parity conversion from NZ dollars to
pounds sterling of 2.24 [48], the mean ICUR is £9333, which is well
below the revealed WTP of £20,000 to £30,000 in the United
Kingdom [49–51]. Therefore, if the therapy were to be evaluated
on the same basis as novel pharmaceuticals in the United King-
dom, it would be considered to be fundable there, subject to
available resources and all other factors being equal.
Patients were encouraged to use the equipment daily, just as
they take preventive medicines, for 2 hours per day. Adherence,
however, was less than optimal, at a mean duration of 1.6 hours
per day. The cost-effectiveness of the LTHT intervention is likely
to improve with better adherence, as the application of warmed,
humidiﬁed air probably acts by improving lung mucociliary
clearance [12] and is therefore likely to be more effective as the
daily duration of usage is increased. Conversely, shorter periods of
daily use, or intermittent use, would result in a less cost-effective
therapy because the cost of the intervention would be the same or
similar and the health beneﬁts would probably be lower. It will be
important for clinicians to stress to patients the need for pro-
longed daily use of LTHT, just as they stress the need to take long-
acting medications such as oral steroids regularly.
Study Limitations
The clinical trial was (necessarily) unblinded, raising the possi-
bility of a placebo improvement in quality of life. A real improve-
ment in quality of life could be expected because the clinical trial
reported signiﬁcant differences in lung function favoring the
treatment group at 3 months that persisted at 12 months [12].
We cannot, however, rule out the possibility that a placebo effect
contributed to the observed improvement in quality of life and
the SGRQ total score and the cost-effectiveness of the therapy.
Our analysis uses health state utility values that were derived
indirectly from a well-validated questionnaire (the SGRQ). Utility
values mapped from the SGRQ are not available for New Zealand
but they differ between the United Kingdom and the United
States, suggesting that a more reliable result could be obtained if
NZ utility values for patients with COPD could be established. The
UK values, however, could be more generalizable to Europe.
The algorithm for converting SGRQ total scores to health state
utilities carries its own degree of uncertainty, which we were not
able to incorporate into our analysis [19]. The ﬁndings therefore
are somewhat less certain than indicated, although the mean
ICUR is unlikely to change much if the uncertainty of the
algorithm were to be incorporated. Future studies should meas-
ure quality of life prospectively using the short-form 36 health
survey or the EQ-5D questionnaire or some other multiattribute
utility scoring methodology.
Although resource consumption was generally lower in the
treatment group than in the control group, the difference in costs
did not reach statistical signiﬁcance, probably because the study
was not powered for this end point. Because limited information
on resource utilization was available from the clinical trial, our
analysis combined resource consumption based on patient diarieswith prices obtained from external sources. A one-way sensitivity
analysis showed that excluding the 17 patients who had less than
9 months of diary data gave a higher incremental utility and a
lower cost-utility ratio, suggesting that our analysis was conser-
vative. Descriptively, these 17 patients did not seem to differ
greatly from the remaining 70 used in our main analyses, except
that the time to ﬁrst exacerbation was lower for these 17 patients
(34 days vs. 117 days). Formally comparing 17 to 70 patients cannot
be carried out with much power. Further research is required to
determine whether there is any relationship between noncom-
pliance with diary completion and quality of life.
The main driver of clinical costs was hospital admissions, with
diagnosis-speciﬁc costs estimated from national cost weights that
were determined from more than 15,000 respiratory admissions
to reduce the inﬂuence of outliers [28]. National DRG-based costs
have the virtue of being generalizable across New Zealand, but
they are rather crude measures of admission costs. More accurate
information could be obtained prospectively by a bottom-up
analysis of resource consumption in hospital for each patient in
the clinical trial, including pharmaceuticals other than antibiotics
and prednisone. These costs would be more accurate but less
generalizable than DRG-based national costs across hospitals.
The other source of resource consumption was patient diaries,
whose accuracy cannot be veriﬁed retrospectively. In the base-
case analysis, we extrapolated from a minimum of 3 months of
diary data up to 12 months, and in a sensitivity analysis, we
tightened the restrictions to a minimum of 9 months of patient
diary data. The ﬁndings suggest that we have taken a conserva-
tive approach in our base-case analysis. Changes in the con-
sumption of medications will have little effect on the ﬁndings of
this study.Conclusions
When added to usual care, LTHT improves quality of life and is
moderately cost-effective at WTP thresholds that are in the
acceptable range for reimbursement of new medicines in New
Zealand. If LTHT were to be evaluated on the same basis as new
pharmaceuticals in the United Kingdom, it would probably be
considered to be fundable there. These ﬁndings, however, must
be interpreted with caution because of the modest size of the
clinical study, necessary lack of blinding, and the uncertainty
inherent in estimating utility values indirectly from SGRQ values.
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